Cargando…

Model-based evaluation of the cost effectiveness of 3 versus 6 months’ adjuvant chemotherapy in high-risk stage II colon cancer patients

BACKGROUND: Our aim was to evaluate the cost effectiveness of 3 months’ adjuvant chemotherapy versus 6 months in high-risk (T4 stage + microsatellite stable) stage II colon cancer (CC) patients. METHODS: Using the validated PATTERN Markov cohort model, which simulates the disease progression of stag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jongeneel, Gabrielle, Greuter, Marjolein J. E., van Erning, Felice N., Koopman, Miriam, Vink, Geraldine R., Punt, Cornelis J. A., Coupé, Veerle M. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502861/ https://www.ncbi.nlm.nih.gov/pubmed/32994804 http://dx.doi.org/10.1177/1756284820954114

Ejemplares similares

Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients
por: Jongeneel, Gabrielle, et al.
Publicado: (2021)

Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study
por: Jongeneel, Gabrielle, et al.
Publicado: (2021)

Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data
por: Jongeneel, Gabrielle, et al.
Publicado: (2019)

Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)
por: Jongeneel, Gabrielle, et al.
Publicado: (2020)

Implementation of an optical diagnosis strategy saves costs and does not impair clinical outcomes of a fecal immunochemical test-based colorectal cancer screening program
por: Vleugels, Jasper L. A., et al.
Publicado: (2017)

Management of cytotoxic chemotherapy-induced hand-foot syndrome
por: Kwakman, Johannes J.M., et al.
Publicado: (2020)

Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer
por: Blinman, Prunella, et al.
Publicado: (2020)

Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using (18)F–FDG-PET-CT and/or diffusion-weighted MRI
por: Greuter, Marjolein JE, et al.
Publicado: (2017)

Resilience of a FIT screening programme against screening fatigue: a modelling study
por: Greuter, Marjolein J. E., et al.
Publicado: (2016)

Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data
por: Hamers, Patricia A. H., et al.
Publicado: (2020)

MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer
por: Simmer, Femke, et al.
Publicado: (2015)

Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study
por: Shibahara, Hidetoshi, et al.
Publicado: (2022)

Laparoscopic surgery facilitates administration of adjuvant chemotherapy in locally advanced colon cancer: propensity score analyses
por: Wasmann, Karin ATGM, et al.
Publicado: (2019)

Inventory of oncologists’ unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer
por: Engelhardt, Ellen G., et al.
Publicado: (2018)

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study
por: Schraa, S. J., et al.
Publicado: (2020)

Translation of IDEA trial results into clinical practice: Analysis of the implementation of a new guideline for colon cancer
por: van Rooijen, Karlijn L., et al.
Publicado: (2022)

Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening
por: Bronzwaer, Maxime E. S., et al.
Publicado: (2018)

Time‐varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population‐based study and meta‐analysis
por: van der Kruijssen, Dave E. W., et al.
Publicado: (2022)

The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer
por: Collienne, Maike, et al.
Publicado: (2020)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC
por: Sluiter, Nina R., et al.
Publicado: (2018)

Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals
por: Pumpalova, Yoanna, et al.
Publicado: (2021)

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
por: Lesterhuis, W J, et al.
Publicado: (2010)

Extent and location of tumor infiltrating lymphocytes in microsatellite stable colon cancer predict outcome to adjuvant active specific immunotherapy
por: Turksma, Annelies, et al.
Publicado: (2015)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Adjuvant colon cancer chemotherapy: Is there an Indian standard of care?
por: Joshi, Rohit
Publicado: (2013)

Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer
por: Oki, Eiji, et al.
Publicado: (2021)

Limited effect of lymph node status on the metastatic pattern in colorectal cancer
por: Knijn, Nikki, et al.
Publicado: (2016)

Disease recurrence after colorectal cancer surgery in the modern era: a population-based study
por: Qaderi, Seyed M., et al.
Publicado: (2021)

Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada
por: Attard, C.L., et al.
Publicado: (2010)

Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
por: Tan, Sarah Xinhui, et al.
Publicado: (2023)

Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy
por: Eren, Tulay, et al.
Publicado: (2020)

Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study
por: May, Anne M, et al.
Publicado: (2017)

Update on Adjuvant Chemotherapy for Early Breast Cancer
por: Rampurwala, Murtuza M, et al.
Publicado: (2014)

Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial
por: Klaver, Charlotte E L, et al.
Publicado: (2015)

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer
por: Teufel, Andreas, et al.
Publicado: (2015)

Adjuvant chemotherapy for stage II colon cancer: who really needs it
por: Yang, Yan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n6btqq2gmb685nvg5nskjvmasr